Goserelin Endomedica (Goserelin)

Goserelin Endomedica is indicated for the hormonal management of several cancers and benign conditions that depend on sex hormone stimulation.

• Treatment of advanced prostate cancer in men.
• Adjuvant therapy for pre‑menopausal and post‑menopausal breast cancer.
• Management of endometriosis to reduce pelvic pain.
• Reduction of uterine fibroid size and related symptoms.
• Control of central precocious puberty in children.
• Part of hormone‑suppression protocols prior to assisted reproductive techniques.

Side effects of Goserelin Endomedica vary in frequency and severity. Patients should be aware of both common and less frequent serious reactions.

Common

• Hot flashes or sweating.
• Injection site pain or erythema.
• Decreased libido or erectile dysfunction.
• Mood changes such as depression or anxiety.
• Bone mineral density loss over long‑term use.
• Vaginal dryness in women.

Serious

• Cardiovascular events (e.g., myocardial infarction, stroke).
• Severe allergic reactions (anaphylaxis, angioedema).
• Acute adrenal insufficiency.
• Persistent severe osteoporosis leading to fractures.
• Liver function abnormalities.
• Hyperglycemia or new‑onset diabetes mellitus.

Before initiating Goserelin Endomedica, clinicians should evaluate patient history and monitor ongoing therapy.

• Assess cardiovascular risk, especially in patients with existing heart disease.
• Monitor bone health; consider calcium and vitamin D supplementation.
• Evaluate liver and renal function at baseline and periodically.
• Discuss potential impact on fertility and consider sperm or oocyte preservation.
• Counsel patients on possible mood changes and provide mental health support.
• Use caution in patients with diabetes or glucose intolerance.
• Discontinue if severe allergic reaction occurs.

Goserelin Endomedica may interact with other medicines that affect hormone levels or cardiovascular health.

Avoid

• Concurrent use of other GnRH agonists or antagonists.
• Strong CYP3A4 inhibitors that could alter hormone metabolism.
• Medications that significantly prolong QT interval.

Use with caution

• Anticoagulants (e.g., warfarin) due to potential changes in coagulation.
• Bisphosphonates or denosumab when managing bone loss.
• Antidepressants, as mood alterations may be additive.
• Insulin or oral hypoglycemics, given possible effects on glucose control.
• Hormone replacement therapy, which may counteract intended suppression.